Core Insights - Aptevo Therapeutics reported that 89% of evaluable frontline AML patients achieved remission in combination therapy across two trials, with a notable 100% remission rate in Cohort 3 of the ongoing RAINIER trial [1][1][1] - The company introduced its first trispecific molecules, APVO451 and APVO452, aimed at overcoming immune suppression in certain solid tumors, utilizing a unique CRIS-7-derived CD3 binding domain [1][1][1] - Aptevo's CD3 T-cell engager portfolio has been expanded to five molecules, indicating growth in its therapeutic offerings [1][1][1] - The company raised $18.7 million in the third quarter and an additional $4.1 million since the quarter ended, extending its cash runway into the fourth quarter of 2026 [1][1][1] Financial Performance - The financial results for the quarter ended September 30, 2025, were reported alongside a business update, highlighting the company's ongoing development in immune-oncology therapeutics [1][1][1]

Core Insights - Aptevo Therapeutics is actively participating in several key financial, industry, scientific, and medical conferences this fall to showcase its ongoing developments and momentum in the biotechnology sector [1] Conference Participation - Aptevo will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, discussing its lead asset mipletamig and its clinical progress in Acute Myeloid Leukemia (AML) [1] - The company will also be present at the Biotechnology Innovation Organization (BIO)-Europe 2025 from November 3-5, 2025, engaging in meetings at the largest biotechnology event in Europe [1] - At the Society of Immunotherapy in Cancer (SITC) 2025, scheduled for November 5-9, 2025, Aptevo's R&D team will present a poster on a novel trispecific targeting approach to address the immunosuppressive tumor microenvironment [1] - The interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mipletamig in frontline combination therapy for AML will be presented at the American Society of Hematology (ASH) 2025 meeting from December 6-9, 2025 [1]

Group 1: Telomir Pharmaceuticals Inc - Telomir Pharmaceuticals Inc's shares rose 31% to $1.86 in pre-market trading following the release of promising preclinical study results for its lead compound, Telomir-1 [1] - The preclinical study indicated that Telomir-1 was able to reverse abnormal DNA methylation in aggressive prostate cancer models [1] Group 2: Other Stocks in Pre-Market Trading - Spruce Biosciences Inc gained 90.9% to $248.89, while C3is Inc surged 73.3% to $3.83 in pre-market trading [5] - Aptevo Therapeutics Inc increased by 40.2% to $1.98, and Galecto Inc rose 37.5% to $5.10 [5] - Datavault AI Inc surged 27.8% to $2.66, reaffirming its 2H 2025 revenue guidance of $12 million to $15 million [5] - Processa Pharmaceuticals Inc gained 27.5% to $0.36, and BTQ Technologies Corp rose 25.7% to $11.44 [5] - DBV Technologies SA gained 12.8% to $14.99 after announcing the sale of approximately $30 million of ADSs [5] - Amkor Technology Inc jumped 11.2% to $33.99, announcing an expanded investment in semiconductor packaging and testing in Arizona [5] Group 3: Declining Stocks - Society Pass Inc shares dipped 24.6% to $4.00 after a significant jump of 276% on Monday [5] - Dermata Therapeutics Inc fell 19.1% to $4.35, and Aether Holdings Inc declined 16.8% to $4.51 [5] - SANUWAVE Health Inc dipped 14.4% to $34.99, cutting its FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [5] - Lazydays Holdings Inc fell 12.3% to $2.57, while NOVONIX Ltd tumbled 12.3% to $1.57 [5] - OneMedNet Corp dipped 12.1% to $2.25 after a significant jump of 149% on Monday [5]

As filed with the Securities and Exchange Commission on October 1, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 81-1567056 (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 2401 4th Avenue, ...

Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 150 points, closing up 0.37% at 46,190.85, NASDAQ rising 1.07% to 22,500.28, and S&P 500 gaining 0.62% to 6,641.29 [1] - In the commodities market, oil prices rose by 0.7% to $64.50, while gold decreased by 1.2% to $3,674.30 [5] Company Performance - Darden Restaurants, Inc. reported first-quarter earnings of $1.97 per share, missing the analyst consensus estimate of $2.00 per share, and quarterly sales of $3.004 billion, which also fell short of the $3.040 billion estimate [2] - 89bio, Inc. shares surged 86% to $15.02 following an acquisition agreement with Roche [8] - Intel Corporation's shares increased by 27% to $31.59 after announcing a partnership with NVIDIA for AI infrastructure development, with NVIDIA investing $5 billion in Intel's stock at $23.28 per share [8] - Aptevo Therapeutics Inc. saw its shares rise by 62% to $2.2863 due to breakthrough clinical results for its drug in AML treatment [8] - Replimune Group, Inc. shares fell by 39% to $3.4900 as the company assesses FDA feedback on its product [8] - BioCardia, Inc. shares dropped 29% to $1.0850 after announcing a public offering and trial results [8] - Lifeway Foods, Inc. shares decreased by 21% to $26.72 following Danone's withdrawal of its acquisition proposal [8] Economic Indicators - U.S. initial jobless claims decreased by 33,000 to 231,000, better than the market estimate of 240,000 [10] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest since January, compared to -0.3 in August [10] European and Asian Markets - European shares showed positive movement, with the eurozone's STOXX 600 rising by 0.79% and major indices in Spain, London, Germany, and France also gaining [6] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% while Hong Kong's Hang Seng fell by 1.35% [7]

Market Overview - U.S. stocks traded mostly higher, with the Nasdaq Composite gaining over 100 points on Thursday [1] - The Dow decreased by 0.04% to 46,000.59, while the NASDAQ rose by 0.49% to 22,370.12 and the S&P 500 increased by 0.29% to 6,619.34 [1] Sector Performance - Information technology shares increased by 0.8% on Thursday [1] - Materials stocks fell by 0.7% [2] Economic Indicators - U.S. initial jobless claims declined by 33,000 to 231,000 in the second week of September, better than market estimates of 240,000 [3][9] - The Philadelphia Fed Manufacturing Index rose to +23.2 in September, the highest level since January, compared to -0.3 in August [11] Commodity Prices - Oil prices increased by 0.5% to $64.37, while gold decreased by 0.4% to $3,701.70 [6] - Silver fell by 0.1% to $42.110 and copper dropped by 0.5% to $4.6135 [6] International Markets - European shares were higher, with the eurozone's STOXX 600 rising by 0.8% [7] - Asian markets closed mixed, with Japan's Nikkei gaining 1.15% and Hong Kong's Hang Seng falling by 1.35% [8] Company News - 89bio, Inc. shares surged 85% to $14.97 after announcing an acquisition agreement with Roche [10] - Aeries Technology, Inc. shares also rose 85% to $1.0500 following a partnership announcement with an annual contract value of up to $8 million [10] - Aptevo Therapeutics Inc. shares increased by 57% to $2.2201 after breakthrough clinical results [10] - Replimune Group, Inc. shares dropped by 40% to $3.4288 as the company evaluates FDA feedback [10] - BioCardia, Inc. shares fell by 34% to $1.02 after announcing a public offering and trial results [10] - Office Properties Income Trust shares decreased by 28% to $0.4066 [10]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Core Insights - Aptevo Therapeutics Inc. (APVO) experienced a significant stock increase of 46.10% to $2.06 after reporting breakthrough clinical results for its drug aimed at treating acute myeloid leukemia (AML) [1] Clinical Trial Results - The Phase 1b/2 RAINIER trial showed a perfect remission rate, with all patients in Cohort 3 achieving complete remission using mipletamig in combination with venetoclax and azacitidine [2] - No dose-limiting toxicities or cytokine release syndrome were reported across all cohorts of the trial, indicating a favorable safety profile [2] Market Opportunity and Future Steps - The frontline AML market represents a multi-billion-dollar opportunity, with current standard treatments yielding lower remission rates compared to those observed in the RAINIER trial [3] - 40% of patients in the trial achieved minimal residual disease-negative status, which is a positive indicator for prognosis [3] - Enrollment for Cohort 4 is ongoing at higher dose levels, with a conference presentation anticipated in the fourth quarter [3] Stock Performance Overview - APVO's stock has seen a decline of approximately 31.9% from its one-month peak of $2.07 to a close of $1.41 [4] - Over the past year, the stock has decreased by 98.84%, and it is down 98.36% year-to-date in 2025 [4] - The clinical-stage stock has an annual trading range between $1.32 and $381.10, with a market capitalization of $4.64 million and an average trading volume of 3.98 million shares [4]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has bureaus and studios in key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company is focused on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4] - Automation and software tools, including generative AI, are used, but all content is edited and authored by humans [5]

Market Overview - The S&P 500 and Nasdaq Composite experienced slight declines of less than 0.1%, while the Dow Jones Industrial Average fell by nearly 0.3%, indicating cautious market sentiment ahead of the Federal Reserve's interest rate decision [1][8][21] - Fund managers are the most bullish on stocks since February, according to Bank of America's latest survey, but investors are exercising caution ahead of the Fed's rate call [8][21] Federal Reserve Meeting - The Federal Reserve's two-day policy meeting commenced under unusual political tension, with an appeals court blocking President Trump's attempt to remove Fed governor Lisa Cook, allowing her to participate in the discussions [2][10][12] - Market participants are anticipating a 25 basis point rate cut with a 96% probability, while only a 4% chance is assigned to a larger half-point move [3][11][20] Retail Sales and Economic Indicators - The Commerce Department reported that August retail sales rose by 0.6%, significantly above the expected 0.2% increase, driven by strong clothing and e-commerce spending [9][21] - July retail sales were also revised higher, highlighting the resilience of US consumers despite slower hiring and persistent inflation [9][21] Individual Company Performances - Oracle shares surged nearly 3% following news of its involvement in a US-China TikTok deal, allowing the app to continue operating in the US under new oversight [6][18] - Tesla's stock gained about 1% after CEO Elon Musk purchased shares, erasing earlier year-to-date losses [6][18] - Novo Nordisk shares rose over 2% due to positive developments in its obesity drug research, despite being down approximately 30% year-to-date [7][18] Commodity Market - Gold prices reached a record high above $3,700 per ounce, up 44% year-to-date, driven by a weaker US dollar and expectations of Fed rate cuts [7][18]